NO and angiogenesis

被引：220

作者：

Cooke, JP ^{[1
]}

机构：

[1] Stanford Univ, Sch Med, Program Vasc Med & Biol, Stanford, CA 94305 USA

来源：

ATHEROSCLEROSIS SUPPLEMENTS | 2003年 / 4卷 / 04期

关键词：

angiogenesis; asymmetric dimethylarginine; HMG coA reductase inhibition; L-arginine; NOS;

D O I：

10.1016/S1567-5688(03)00034-5

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Angiogenesis requires the elaboration of endothelium-derived nitric oxide (NO). Angiogenic factors induce the release of NO from endothelial cells, which mediates a multiplicity of processes involved in angiogenesis. These NO-modulated processes include endothelial cell survival, proliferation, migration, and interaction with the extracellular matrix. Derangements of the NO synthase pathway impair angiogenesis. Accordingly, the competitive inhibitor of the NOS pathway asymmetric dimethylarginine (ADMA) acts as an endogenous inhibitor of angiogenesis. By contrast, agents which increase NO synthesis, such as low dose statins, enhance angiogenesis. Modulation of the NO synthase pathway could become a new therapeutic avenue for angiogenesis-related disorders. (C) 2003 Elsevier Ireland Ltd. All rights reserved.

引用

页码：53 / 60

页数：8

共 80 条

[51] OCCURRENCE OF A NEW ENZYME CATALYZING THE DIRECT CONVERSION OF NG,NG-DIMETHYL-L-ARGININE TO L-CITRULLINE IN RATS [J].

OGAWA, T ;

KIMOTO, M ;

SASAOKA, K .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1987, 148 (02) :671-677

[52] HYPERCHOLESTEROLEMIA INCREASES ENDOTHELIAL SUPEROXIDE ANION PRODUCTION [J].

OHARA, Y ;

PETERSON, TE ;

HARRISON, DG .

JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (06) :2546-2551

[53] Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells [J].

Papapetropoulos, A ;

García-Cardeña, G ;

Madri, JA ;

Sessa, WC .

JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (12) :3131-3139

[54]

Papapetropoulos A, 1997, AM J PATHOL, V150, P1835

[55] 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA [J].

Park, HJ ;

Kong, DQ ;

Iruela-Arispe, L ;

Begley, U ;

Tang, DJ ;

Galper, JB .

CIRCULATION RESEARCH, 2002, 91 (02) :143-150

[56] Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering [J].

Pedersen, TR ;

Wilhelmsen, L ;

Færgeman, O ;

Strandberg, TE ;

Thorgeirsson, G ;

Troedsson, L ;

Kristianson, J ;

Berg, K ;

Cook, TJ ;

Haghfelt, T ;

Kjekshus, J ;

Miettinen, T ;

Olsson, AG ;

Pyörälä, K ;

Wedel, H .

AMERICAN JOURNAL OF CARDIOLOGY, 2000, 86 (03) :257-262

[57]

POU S, 1992, J BIOL CHEM, V267, P24173

[58] Inhibition of monocyte chemotactic protein-1 synthesis by statins [J].

Romano, M ;

Diomede, L ;

Sironi, M ;

Massimiliano, L ;

Sottocorno, M ;

Polentarutti, N ;

Guglielmotti, A ;

Albani, D ;

Bruno, A ;

Fruscella, P ;

Salmona, M ;

Vecchi, A ;

Pinza, M ;

Mantovani, A .

LABORATORY INVESTIGATION, 2000, 80 (07) :1095-1100

[59] Nitric oxide inhibits caspase-3 by S-nitrosation in vivo [J].

Rössig, L ;

Fichtlscherer, B ;

Breitschopf, K ;

Haendeler, J ;

Zeiher, AM ;

Mülsch, A ;

Dimmeler, S .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (11) :6823-6826

[60]

RUBANYI GM, 1986, AM J PHYSIOL, V250, pH822, DOI 10.1152/ajpheart.1986.250.5.H822

← 1 2 3 4 5 6 7 8 →